Opentrons Raises $40M Series E for Autonomous Science

Thousands of installed laboratory robots give Opentrons an unusual place to begin selling its vision of autonomous science. The New York laboratory automation company already has equipment on scientists' benches, where experimental instructions have to survive contact with samples, instruments and the working habits of a lab.

Opentrons Labworks announced a $40M Series E financing on October 29, 2026, led by healthcare investor Avego with participation from BroadOak Capital Partners. CEO James Atwood plans to expand robotics, software and data infrastructure, including AI-driven experimental execution and connections with other laboratory tools. The investment supports an effort to make the installed instrument base useful within a larger cycle of planning experiments, carrying them out and learning from the results.

For research organizations, that proposition reaches into the relationship between laboratory staff and software suppliers. A system suggesting an experiment must eventually meet equipment capable of performing it, and the resulting data must remain useful to the people deciding what to investigate next. Opentrons is financing more of that journey across the bench.

What the Series E finances

The new capital backs a collection of work around experimental execution: faster protocol development, expanded robot and instrument capabilities, deeper ecosystem integration, and entry into new markets and geographies. Those are Opentrons' stated plans for the financing. The company has not supplied a public allocation showing how much of the $40M will go to each activity or a timetable for delivering every part of the expansion.

Avego brings a healthcare investment perspective to the round. Its managing partner James Flexner appears in the announcement, linking the investment case to drug developers and AI companies seeking automated experimental workflows. BroadOak Capital Partners is the disclosed additional participant. Earlier backers belong to a different part of the financing history: Opentrons' official archive records a $200M Series C led by SoftBank Vision Fund 2 in September 2021, with participation from Khosla Ventures.

The Series E places fresh resources behind a broader product assignment than selling a liquid-handling instrument. Software has to help turn an intended experiment into an executable protocol, while integrations determine how far that protocol can travel through a laboratory's existing equipment. That makes the usefulness of the surrounding workflow commercially significant: it shapes what a scientist can do after the robot has been purchased and installed.

The installed base creates a route into the lab

Opentrons says it has deployed more than 11,000 robots across more than 80 countries. That company-reported footprint gives its software strategy an established hardware starting point. It also contains many different laboratory environments, so the deployment count should be read as a measure of physical reach rather than a count of laboratories already running autonomous experiments.

The company's Flex platform uses modular pipettes, a gripper and interchangeable hardware to support different workflows. Its OT-2 platform addresses core liquid-handling applications. Opentrons' software documentation describes tools for creating protocols and running them on the robots, placing the link between a scientist's instructions and instrument behavior inside the product itself.

For a research buyer, the modular design creates a practical purchasing conversation. A lab can ask which parts of its current experimental routine fit the available configuration, which require other instruments and how the software will represent those steps. This is an operating implication of the product architecture, rather than a claim that every workflow can already be automated. The equipment and protocol have to suit the actual scientific task.

That distinction matters as AI becomes involved in experiment planning. More proposed experiments create demand for execution capacity, while each lab still needs to understand the work it authorizes. Opentrons' opportunity lies partly in making those decisions easier to carry from planning software into repeatable instrument operations, without asking the laboratory to rebuild its entire working environment around one supplier.

HighRes shows how the partner relationship enters the product

A February partnership with HighRes makes that integration problem tangible. The companies described connecting Opentrons Flex and OpentronsAI with HighRes' Cellario orchestration software and FlexPod automation platform. The collaboration aimed to bring accessible laboratory robotics into workflows coordinated across a broader set of instruments.

HighRes subsequently reported in its Q2 2026 innovation update that the partners had demonstrated an agent-to-agent workflow for qPCR, a method used to measure DNA amplification. Its account describes natural-language intent moving through protocol creation and execution to analyzed results. This provides a specific example of software systems cooperating around physical laboratory work; its scope remains the demonstrated workflow described by the partners.

The commercial implication is that another supplier's software can become part of the route into Opentrons' equipment. A lab purchasing automation may already have instruments, scheduling tools and data practices it intends to retain. Interoperability lets the conversation begin with that existing environment, giving the laboratory a way to consider additional capabilities alongside earlier investments.

It also gives the suppliers a continuing coordination job. Protocol generation, instrument scheduling and the interpretation of results touch different parts of an experimental process. As those connections become a larger part of the product promise, a research team needs to understand which system performs each step and how its output reaches the next participant. The partnership illustrates why expanding laboratory automation requires relationships between vendors as well as additional robot capabilities.

Leadership carries the software ambition forward

James Atwood became CEO in July 2025, according to the company's January 2026 leadership announcement. Opentrons' current leadership page also identifies co-founders William Canine and Chiu Chau. Y Combinator's company record dates the business to 2014 and identifies Nicholas Wagner as a former founder, preserving the distinction between the company's origins and its current management.

The financing extends a long-running effort to make lab robotics more accessible into a software-intensive phase. That continuity helps explain why the deployed equipment matters: it gives Opentrons a foundation for introducing new protocol and integration capabilities into a market it already serves. The Series E announcement leaves revenue, robot utilization and a current valuation undisclosed, so the public evidence supports an account of the strategy and footprint rather than a calculation of its economics.

For James Atwood's team, expansion now includes helping more laboratories connect what they want to learn with the instruments that can produce the evidence. Each additional integration puts Opentrons into a new conversation with the people responsible for keeping experimental work understandable, repeatable and useful after the run finishes.